Cumberland Partners Ltd Purchases 8,000 Shares of ResMed Inc. $RMD

The article is a promotional piece claiming AI could be worth $250 trillion by 2040, citing Elon Musk’s estimate of 10 billion humanoid robots priced at $20,000–$25,000. It also advertises a newsletter and alleges an “underdog” stock trading at about $3 has cut $100 million in waste and offers “400% upside,” but it provides no verifiable company details.

Angelini Ventures said its portfolio company Noctrix Health was acquired by ResMed (NYSE: RMD) in a $340 million deal. Noctrix develops wearable, clinically validated neuromodulation therapies; its lead product Nidra is FDA-authorized for moderate-to-severe restless legs syndrome. Angelini Ventures invested in 2024’s $40 million Series C. The exit is described as its first.

The article says the S&P/ASX 200 Health Care Index is about 33% lower year-to-date, making healthcare the worst ASX sector in 2026, citing earnings downgrades, higher costs, weaker overseas earnings and slower growth concerns. It highlights Pro Medicus (up 9% to $144.46; broker target $187.27), ResMed (52-week low $26.27; Morgans target $41.72) and Sonic Healthcare (target $23.40).

The ASX 200 closed virtually flat at 8,729.40, down 0.026%, after dipping to 8,700 before buyers returned. The Information Technology sector rose 5.43% to 1,869.40, led by Pro Medicus (+9.22% to $144.46), WiseTech Global (+8.72% to $39.15) and Xero (+7.69% to $80.95). Brazilian Rare Earths (-10.74% to $5.90) and DroneShield (-8.56% to $3.10) were among the biggest decliners.

Thrivent Financial for Lutherans significantly increased its stake in ResMed Inc. (NYSE:RMD) during the fourth quarter of 2025, purchasing an additional 11,481 shares and bringing its total holdings to 22,408 shares valued at $5.43 million. Other institutional investors also adjusted their positions in ResMed, which recently reported strong quarterly earnings, beating analyst expectations, and announced a quarterly dividend of $0.60 per share. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for ResMed.

ResMed Inc. (RMD) is gaining investor attention due to unusual options activity suggesting higher volatility and its stock trading near recent highs on the NYSE. The company specializes in medical devices and digital health solutions for sleep apnea and chronic respiratory conditions, leveraging a business model that combines hardware and cloud-based software. For US investors, ResMed offers exposure to structural healthcare growth trends, though it requires careful consideration of reimbursement policies and market dynamics.